ArticleOncoTargets and therapy2016

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.

Victor Jeannot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.